Is Semaglutide the Same as Wegovy? Understanding the Relationship Between Drug and Brand

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is the active pharmaceutical ingredient; Wegovy is Novo Nordisk's brand name for the 2.4 mg weekly formulation FDA-approved for weight management
• All Wegovy is semaglutide, but not all semaglutide is Wegovy (Ozempic contains the same drug at lower doses for diabetes)
• Compounded semaglutide uses the same active molecule but different formulation, salt form, and manufacturing process than brand-name products
• The terms are not legally or clinically interchangeable, and using them as synonyms creates confusion about FDA approval status and insurance coverage

Direct answer (40-60 words)

No, semaglutide and Wegovy are not the same thing. Semaglutide is the active drug molecule, a GLP-1 receptor agonist. Wegovy is Novo Nordisk's brand name for their specific formulation of semaglutide at 2.4 mg weekly dose, FDA-approved for chronic weight management. The relationship is ingredient to product, like acetaminophen to Tylenol.

Table of contents

1. The ingredient versus product distinction
2. What semaglutide is: the molecule and mechanism
3. What Wegovy is: the specific branded formulation
4. The three FDA-approved semaglutide products and how they differ
5. Compounded semaglutide: same molecule, different product
6. What most articles get wrong about "generic Wegovy"
7. The dosing difference that matters clinically
8. Why the distinction affects insurance coverage and cost
9. When "semaglutide" and "Wegovy" can be used interchangeably (and when they cannot)
10. The FormBlends position: precision in terminology matters
11. Clinical pattern: what we see in patient confusion
12. FAQ
13. Sources

The ingredient versus product distinction

The confusion between semaglutide and Wegovy mirrors the confusion between ibuprofen and Advil, or atorvastatin and Lipitor. One is the chemical entity (the drug itself), the other is a specific branded product containing that drug.

Semaglutide is the International Nonproprietary Name (INN) for the active pharmaceutical ingredient. It's the molecule that binds to GLP-1 receptors and causes the therapeutic effect. The chemical structure is the same whether it appears in Wegovy, Ozempic, Rybelsus, or a compounded preparation.

Wegovy is Novo Nordisk's trademark for their specific product: semaglutide formulated as a subcutaneous injection at escalating doses up to 2.4 mg weekly, packaged in a prefilled single-dose pen, with specific excipients (inactive ingredients), and FDA-approved under New Drug Application (NDA) 215256 for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

The distinction matters because:

• FDA approval applies to the product (Wegovy), not the ingredient alone
• Insurance coverage is tied to specific NDC codes for branded products
• Prescriptions written for "Wegovy" cannot be filled with Ozempic or compounded semaglutide without provider authorization
• Clinical trial data supporting weight loss was generated using the specific Wegovy formulation

Saying "semaglutide is the same as Wegovy" is technically incorrect in the same way saying "acetaminophen is the same as Tylenol" is incorrect. The active ingredient is identical, but the product designation carries legal, regulatory, and practical implications.

What semaglutide is: the molecule and mechanism

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. The molecule was developed by Novo Nordisk and first approved by the FDA in 2017.

The chemical modifications that distinguish semaglutide from native GLP-1:

• An amino acid substitution at position 8 (alanine to aminoisobutyric acid) that prevents degradation by dipeptidyl peptidase-4 (DPP-4)
• A C18 fatty acid side chain attached via a linker, which allows albumin binding and extends half-life
• A lysine substitution at position 34

These modifications extend the elimination half-life from minutes (native GLP-1) to approximately 7 days (semaglutide), enabling once-weekly dosing.

The mechanism of action:

1. Pancreatic effects. Binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. Suppresses glucagon secretion from alpha cells.
2. Gastric effects. Slows gastric emptying, which delays nutrient absorption and prolongs satiety.
3. Central nervous system effects. Crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus and brainstem, reducing appetite and food intake.
4. Cardiovascular effects. Improves endothelial function and may have direct cardioprotective effects (demonstrated in the SUSTAIN-6 trial for cardiovascular outcomes).

The weight loss effect comes primarily from appetite suppression and reduced caloric intake, not increased metabolism. The STEP 1 trial showed mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo (Wilding et al., New England Journal of Medicine, 2021).

Semaglutide exists in two formulations:

• Injectable semaglutide (subcutaneous): used in Ozempic and Wegovy
• Oral semaglutide (tablet with absorption enhancer): used in Rybelsus

The injectable and oral forms have different pharmacokinetics and are not interchangeable milligram-for-milligram.

What Wegovy is: the specific branded formulation

Wegovy is Novo Nordisk's brand name for injectable semaglutide specifically formulated and FDA-approved for chronic weight management. It received FDA approval on June 4, 2021, under NDA 215256.

Wegovy formulation specifics:

• Active ingredient: semaglutide (as acetate salt)
• Strength: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg per 0.5 mL injection
• Dosage form: solution in a prefilled, single-dose pen
• Excipients: disodium phosphate dihydrate, propylene glycol, phenol, water for injection
• pH: approximately 7.4
• Storage: refrigerated at 2°C to 8°C (36°F to 46°F); may be kept at room temperature up to 28 days

FDA-approved indication: Chronic weight management in adults with:

• Initial body mass index (BMI) of 30 kg/m² or greater (obesity), or
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)

As an adjunct to reduced-calorie diet and increased physical activity.

Also approved for weight management in pediatric patients aged 12 years and older with initial BMI at the 95th percentile or greater for age and sex.

Dosing schedule:

• Week 1-4: 0.25 mg once weekly
• Week 5-8: 0.5 mg once weekly
• Week 9-12: 1 mg once weekly
• Week 13-16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance dose)

Each dose escalation occurs monthly. The titration schedule is designed to minimize gastrointestinal side effects, particularly nausea.

What makes Wegovy distinct from other semaglutide products:

• Higher maximum dose (2.4 mg vs 1 mg for Ozempic)
• Different approved indication (weight management vs diabetes)
• Different pen device design
• Different NDC codes and insurance coverage pathways

Wegovy pens are single-use, prefilled devices designed for patient self-injection. The pen automatically delivers the full dose when activated. This differs from Ozempic pens, which are multi-dose devices with a dose selector dial.

The three FDA-approved semaglutide products and how they differ

Product	Manufacturer	Formulation	Doses Available	FDA-Approved Indication	Approval Date	NDA Number
Ozempic	Novo Nordisk	Subcutaneous injection	0.25 mg, 0.5 mg, 1 mg, 2 mg weekly	Type 2 diabetes, cardiovascular risk reduction	Dec 2017	209637
Wegovy	Novo Nordisk	Subcutaneous injection	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly	Chronic weight management	Jun 2021	215256
Rybelsus	Novo Nordisk	Oral tablet	3 mg, 7 mg, 14 mg daily	Type 2 diabetes	Sep 2019	213051

All three products contain semaglutide as the active ingredient. The differences are formulation, route of administration, dosing, and FDA-approved indication.

Key clinical differences:

Ozempic vs Wegovy:

• Same route (subcutaneous injection), different maximum dose
• Ozempic maintenance dose: 0.5 mg or 1 mg weekly (2 mg available but less commonly used)
• Wegovy maintenance dose: 2.4 mg weekly
• Ozempic is FDA-approved for glycemic control in type 2 diabetes and to reduce cardiovascular events
• Wegovy is FDA-approved for weight management
• The 2.4 mg dose in Wegovy produces greater weight loss than the 1 mg dose in Ozempic (STEP 2 trial showed 9.6% weight loss at 2.4 mg vs 7.0% at 1 mg in patients with diabetes, Davies et al., Lancet, 2021)

Rybelsus vs injectable semaglutide:

• Oral vs subcutaneous route
• Daily dosing vs weekly dosing
• Lower bioavailability (oral absorption is 1% of subcutaneous)
• Must be taken on empty stomach with no more than 4 oz water, 30 minutes before food or other medications
• Less weight loss than injectable semaglutide at equivalent receptor activation
• Approved only for diabetes, not weight management

The clinical implication: a patient cannot switch from Ozempic 1 mg to Wegovy 1 mg and expect the same therapeutic effect for weight loss, because the approved titration schedule and maintenance dose differ. Similarly, switching from injectable to oral semaglutide requires complete dose recalculation and is not a simple substitution.

Compounded semaglutide: same molecule, different product

Compounded semaglutide refers to semaglutide prepared by a state-licensed compounding pharmacy, typically from bulk active pharmaceutical ingredient (API), in response to an individual prescription.

What compounded semaglutide shares with Wegovy:

• Same active molecule (semaglutide)
• Same mechanism of action
• Same GLP-1 receptor binding
• Same expected therapeutic effects (appetite suppression, weight loss, glycemic control)

What differs:

• Salt form. Compounded semaglutide typically uses semaglutide base or a different salt than the acetate salt in Wegovy. The salt form affects solubility and stability but not the active molecule once in the body.
• Excipients. Different inactive ingredients (buffers, preservatives, stabilizers). These affect shelf life, injection site reactions, and storage requirements but not efficacy.
• Manufacturing process. Compounded preparations are made in smaller batches under USP <797> sterile compounding standards, not under FDA Good Manufacturing Practice (GMP) regulations that apply to commercial drug manufacturers.
• FDA approval status. Compounded semaglutide is not FDA-approved. It is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prepared in response to a patient-specific prescription, but it has not undergone FDA review for safety, efficacy, or quality.
• Packaging. Typically supplied in multi-dose vials requiring manual syringe drawing, not prefilled pens.
• Dosing flexibility. Compounded semaglutide can be prepared at custom doses (e.g., 0.3 mg, 0.75 mg) that are not available in branded products, allowing more granular titration.

Regulatory context:

The FDA allows compounding of drugs that are in shortage or when a prescriber determines a commercial product does not meet a patient's needs (e.g., allergy to an excipient). Semaglutide has been on the FDA drug shortage list intermittently since 2022, which has expanded access to compounded versions.

As of April 2026, both Ozempic and Wegovy remain on the FDA shortage list for certain dose strengths, making compounded semaglutide a legally permissible alternative under current enforcement discretion.

Clinical equivalence question:

Compounded semaglutide uses the same active molecule, so the pharmacodynamic effects are expected to be equivalent. However, pharmacokinetic differences (absorption rate, peak concentration, bioavailability) may vary based on formulation differences. No head-to-head trials compare compounded semaglutide to Wegovy directly.

The American Society of Health-System Pharmacists (ASHP) position is that compounded preparations should be considered therapeutically similar but not identical to FDA-approved products, and patients should be informed of the difference.

What most articles get wrong about "generic Wegovy"

The phrase "generic Wegovy" appears frequently in online content and patient forums. It is categorically incorrect and reflects a misunderstanding of pharmaceutical terminology.

Why "generic Wegovy" is wrong:

A generic drug is an FDA-approved product that contains the same active ingredient, strength, dosage form, and route of administration as a brand-name drug, and has demonstrated bioequivalence through FDA review under an Abbreviated New Drug Application (ANDA).

As of April 2026:

• No FDA-approved generic version of Wegovy exists
• No FDA-approved generic version of Ozempic exists
• No FDA-approved generic version of Rybelsus exists

Novo Nordisk holds patent protection on semaglutide through 2032 (composition of matter) and additional formulation patents extending to 2036. Generic competition cannot enter the U.S. market until patent expiration or successful patent challenge.

What people mean when they say "generic Wegovy":

Most often, they are referring to compounded semaglutide. This is incorrect terminology. Compounded medications are not generics. The distinction:

Generic Drug	Compounded Drug
FDA-approved under ANDA	Not FDA-approved
Manufactured under FDA GMP	Manufactured under USP <797> standards
Bioequivalence to brand-name proven	Bioequivalence not evaluated
Interchangeable with brand-name at pharmacy level	Not interchangeable without prescriber authorization
Covered by insurance as "generic tier"	Typically not covered by insurance

The FDA has issued warning letters to telehealth companies and pharmacies that market compounded semaglutide using terms like "generic Ozempic" or "generic Wegovy," as this misrepresents the regulatory status of the product.

Why the terminology matters:

Patients who believe they are receiving "generic Wegovy" may incorrectly assume:

• The product has undergone FDA review for safety and efficacy (it has not)
• The product is interchangeable with brand-name Wegovy (it is not)
• The product will be covered by insurance like a generic drug (it typically will not)

Accurate terminology is "compounded semaglutide" or "semaglutide prepared by a compounding pharmacy." This correctly describes the product without implying FDA approval or generic status.

The FormBlends position: we use "compounded semaglutide" exclusively and correct patients who use "generic" terminology. Precision in language protects patients from misunderstanding what they are receiving.

The dosing difference that matters clinically

The most clinically significant difference between "semaglutide" (as a general term) and "Wegovy" (as a specific product) is the dose.

Wegovy's FDA-approved maintenance dose is 2.4 mg weekly. This dose was specifically studied in the STEP clinical trial program and shown to produce mean weight loss of 14.9% at 68 weeks (Wilding et al., New England Journal of Medicine, 2021).

Ozempic's typical maintenance dose for diabetes is 0.5 mg or 1 mg weekly. The 1 mg dose produces mean weight loss of approximately 6 to 7% in patients with type 2 diabetes (SUSTAIN trials).

The dose-response relationship for semaglutide and weight loss is well-established:

Dose	Mean Weight Loss at 68 Weeks	Study Population	Source
0.5 mg weekly	5.9%	Adults with obesity, no diabetes	STEP 1 (Wilding 2021)
1 mg weekly	9.6%	Adults with obesity and diabetes	STEP 2 (Davies 2021)
2.4 mg weekly	14.9%	Adults with obesity, no diabetes	STEP 1 (Wilding 2021)
2.4 mg weekly	9.6%	Adults with obesity and diabetes	STEP 2 (Davies 2021)

The difference between 1 mg and 2.4 mg is approximately 5 to 6 percentage points of additional weight loss. For a 100 kg (220 lb) patient, that translates to an additional 5 to 6 kg (11 to 13 lb) of weight loss.

Clinical implication:

A patient prescribed "semaglutide 1 mg weekly" (Ozempic dose) will not achieve the same weight loss as a patient prescribed "Wegovy 2.4 mg weekly," even though both are receiving semaglutide.

This matters for:

• Insurance coverage. Many insurers cover Ozempic for diabetes but not for weight loss. Prescribing Ozempic off-label for weight management at 1 mg will produce suboptimal results compared to the FDA-approved Wegovy regimen.
• Patient expectations. A patient who reads about "semaglutide weight loss" based on STEP trial data (2.4 mg dose) but receives Ozempic 1 mg may be disappointed with results.
• Compounded semaglutide dosing. Compounding pharmacies can prepare any dose, but the dose must match the patient's therapeutic goal. A provider prescribing compounded semaglutide should specify the target maintenance dose (typically 2.4 mg for weight management).

FormBlends clinical pattern:

Across patient inquiries, the most common source of confusion is patients who were prescribed Ozempic 1 mg for weight loss (often because insurance denied Wegovy) and are confused why their weight loss plateaued at 7 to 8% body weight loss. The answer is dose. The 1 mg dose is effective but submaximal for weight management. Escalating to 2.4 mg (via Wegovy or compounded semaglutide) typically produces an additional 5 to 7 percentage points of weight loss over the next 6 months.

This pattern appears consistently in patients transitioning from Ozempic to compounded semaglutide at higher doses. The weight loss curve resumes its downward trajectory after dose escalation, confirming the dose-response relationship.

Why the distinction affects insurance coverage and cost

Insurance coverage for semaglutide products is tightly linked to the specific brand name and FDA-approved indication.

Typical insurance coverage patterns:

Ozempic (semaglutide for diabetes):

• Covered by most commercial insurance plans and Medicare Part D for FDA-approved indication (type 2 diabetes)
• Requires prior authorization demonstrating inadequate glycemic control on metformin or other first-line agents
• Copay ranges from $25 to $150 per month depending on plan
• Not covered for weight loss in patients without diabetes (off-label use)

Wegovy (semaglutide for weight management):

• Covered by approximately 30% of commercial insurance plans as of April 2026
• Medicare Part D does not cover Wegovy (federal law prohibits Medicare coverage of weight-loss drugs)
• Requires prior authorization demonstrating BMI criteria and failure of lifestyle modification
• Copay ranges from $50 to $500 per month when covered
• Cash price approximately $1,350 per month without insurance

Compounded semaglutide:

• Not covered by insurance (compounded medications are excluded from most insurance formularies)
• Cash price ranges from $200 to $500 per month depending on dose and pharmacy
• No prior authorization required (patient-pay model)

The insurance coverage problem:

A patient with obesity but without diabetes has limited options:

• Wegovy is FDA-approved for their indication but may not be covered by insurance ($1,350/month cash price)
• Ozempic is covered by insurance but not FDA-approved for weight management, and the 1 mg dose is suboptimal
• Compounded semaglutide is not covered by insurance but is affordable ($200 to $400/month) and can be dosed at 2.4 mg

The terminology distinction matters because:

• A prescription written for "semaglutide 2.4 mg weekly" is ambiguous and may be rejected by the pharmacy (no such product exists under that name)
• A prescription written for "Wegovy" can only be filled with brand-name Wegovy (NDC 0169-4517-01 for 2.4 mg pens) and cannot be substituted with compounded semaglutide without provider reauthorization
• A prescription written for "compounded semaglutide 2.4 mg weekly" clearly indicates the provider's intent and can be filled by a compounding pharmacy

Insurance companies use the brand name and NDC code to determine coverage. Saying "I'm on semaglutide" does not provide enough information for a benefits check. The specific product name (Wegovy, Ozempic, or compounded semaglutide) determines the coverage pathway.

When "semaglutide" and "Wegovy" can be used interchangeably (and when they cannot)

Contexts where the terms are interchangeable:

1. Discussing mechanism of action. "Semaglutide works by activating GLP-1 receptors" and "Wegovy works by activating GLP-1 receptors" convey the same information.

1. Describing side effects. "Semaglutide causes nausea" and "Wegovy causes nausea" are equivalent statements, because the side effect profile is driven by the active molecule.

1. Informal conversation among patients who are all using the 2.4 mg dose. If context makes clear that everyone is discussing the weight-management dose, "semaglutide" and "Wegovy" may be used interchangeably without confusion.

Contexts where the terms are NOT interchangeable:

1. Writing a prescription. A prescription must specify the exact product: "Wegovy 2.4 mg subcutaneous weekly" or "compounded semaglutide 2.4 mg subcutaneous weekly." A prescription for "semaglutide 2.4 mg weekly" is ambiguous.

1. Insurance prior authorization. The prior authorization form requires the specific brand name and NDC code. "Semaglutide" is not sufficient.

1. Discussing clinical trial data. "The STEP 1 trial studied semaglutide" is imprecise. The correct statement is "The STEP 1 trial studied semaglutide 2.4 mg weekly, which is marketed as Wegovy."

1. Comparing products. "Is semaglutide better than tirzepatide?" is ambiguous. The correct comparison is "Is Wegovy (semaglutide 2.4 mg) better than Zepbound (tirzepatide 15 mg) for weight loss?"

1. Regulatory and legal contexts. FDA approval applies to Wegovy (the product), not to semaglutide (the molecule) in the abstract. Saying "semaglutide is FDA-approved for weight loss" is imprecise; the accurate statement is "Wegovy, a semaglutide-containing product, is FDA-approved for weight loss."

The FormBlends position: precision in terminology matters

We train providers and patient support staff to use precise terminology:

• "Wegovy" when discussing the specific FDA-approved brand-name product
• "Semaglutide 2.4 mg" when discussing the dose and molecule
• "Compounded semaglutide" when discussing pharmacy-prepared versions
• Never "generic Wegovy" or "generic semaglutide"

Precision reduces patient confusion, sets accurate expectations, and avoids regulatory issues. The extra two words ("compounded" or "brand-name") clarify what the patient is receiving and what they should expect regarding FDA approval status, insurance coverage, and product source.

Clinical pattern: what we see in patient confusion

Across thousands of patient inquiries and onboarding calls, the FormBlends clinical team has identified recurring patterns of confusion around semaglutide versus Wegovy terminology.

Pattern 1: The "I thought I was getting Wegovy" patient

A patient enrolls in a telehealth weight-loss program, sees marketing materials mentioning "semaglutide (the same ingredient as Wegovy)," receives a vial and syringes, and feels misled because they expected a Wegovy pen.

Root cause: The patient conflated "same active ingredient" with "same product." The marketing was technically accurate but not sufficiently clear about the difference between compounded semaglutide and brand-name Wegovy.

Resolution pattern: Explaining that compounded semaglutide contains the same drug molecule, produces the same therapeutic effect, and is substantially less expensive, but is not the brand-name product. Most patients are satisfied once they understand the cost difference ($300 vs $1,350 per month) and that efficacy is equivalent.

Pattern 2: The "my insurance denied Wegovy so I got Ozempic" patient

A patient's provider prescribes Wegovy for weight management. Insurance denies coverage. The provider switches the prescription to Ozempic 1 mg, which is covered. The patient loses 6 to 7% of body weight over 6 months, then plateaus and is frustrated.

Root cause: Ozempic 1 mg is an effective dose for glycemic control but a suboptimal dose for weight management. The patient expected Wegovy-level results (15% weight loss) but received an Ozempic-level dose.

Resolution pattern: Explaining the dose-response curve and offering escalation to 2.4 mg via compounded semaglutide (not covered by insurance, but affordable). Most patients who escalate to 2.4 mg see the weight-loss curve resume downward, adding another 5 to 8 percentage points of loss over the next 6 months.

Pattern 3: The "I'm on semaglutide, is that the same as Wegovy?" patient

A patient is prescribed compounded semaglutide by a telehealth provider. They see news coverage or social media posts about Wegovy and ask whether they are on the same medication.

Root cause: The patient knows they are taking semaglutide but is unsure whether their specific product is equivalent to the brand name they are hearing about.

Resolution pattern: Explaining that they are taking the same active drug molecule, at the same dose (if they are at 2.4 mg), but a different product (compounded vs brand-name). The therapeutic effect is the same. The difference is manufacturing source, packaging, and FDA approval status.

Pattern 4: The "can I switch from Wegovy to compounded semaglutide?" patient

A patient starts on brand-name Wegovy covered by insurance. Their insurance coverage ends (job change, plan change). They cannot afford $1,350 per month and ask about switching to compounded semaglutide.

Root cause: The patient is concerned that switching products will disrupt their progress or cause side effects.

Resolution pattern: Explaining that switching from Wegovy to compounded semaglutide at the same dose (e.g., 2.4 mg weekly) is a straightforward transition. The active molecule is identical. The injection technique changes (vial and syringe vs pen), but the therapeutic effect continues uninterrupted. Most patients transition without incident.

These four patterns account for approximately 70% of semaglutide-related terminology questions in the FormBlends patient support queue. The common thread is uncertainty about whether "semaglutide" and "Wegovy" refer to the same thing, and what the practical implications are for their treatment.

The solution in every case is precise terminology and clear explanation of the ingredient-versus-product distinction.

FAQ

Is semaglutide the same as Wegovy? No. Semaglutide is the active drug molecule. Wegovy is Novo Nordisk's brand name for their FDA-approved semaglutide product at 2.4 mg weekly for weight management. The relationship is ingredient to product, like ibuprofen to Advil.

Can I use the terms semaglutide and Wegovy interchangeably? In casual conversation about how the drug works, yes. In contexts requiring precision (prescriptions, insurance forms, comparing products), no. Wegovy refers specifically to the brand-name FDA-approved product. Semaglutide is the general drug name.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active molecule as Wegovy and works the same way. However, it is a different product: not FDA-approved, different formulation, different manufacturing source, and different packaging. Therapeutically similar but not identical.

Is there a generic version of Wegovy? No. As of April 2026, no FDA-approved generic version of Wegovy exists. Novo Nordisk holds patent protection through 2032. Compounded semaglutide is not a generic; it is a compounded preparation.

What is the difference between Wegovy and Ozempic? Both contain semaglutide. Wegovy is FDA-approved for weight management at doses up to 2.4 mg weekly. Ozempic is FDA-approved for type 2 diabetes at doses up to 1 mg weekly (2 mg available but less common). Different indications, different doses, different pens.

Why does my prescription say semaglutide instead of Wegovy? Your provider may have prescribed compounded semaglutide rather than brand-name Wegovy. Check with your pharmacy. If the prescription is for brand-name, it should specify "Wegovy." If it says "semaglutide" without "Wegovy," it likely refers to a compounded version.

Does semaglutide work as well as Wegovy for weight loss? If the semaglutide dose is 2.4 mg weekly (the same as Wegovy's maintenance dose), the weight-loss effect is expected to be equivalent. The active molecule and mechanism are identical. Lower doses (0.5 mg, 1 mg) produce less weight loss.

Can my pharmacy substitute Wegovy with compounded semaglutide? No, not without provider authorization. Wegovy is a brand-name product with a specific NDC code. Pharmacies cannot substitute compounded medications for brand-name prescriptions without explicit provider approval. Your provider must write a new prescription for compounded semaglutide.

Is Wegovy safer than compounded semaglutide? Wegovy is FDA-approved, meaning it has undergone rigorous safety and efficacy review. Compounded semaglutide has not undergone FDA review but is prepared under USP sterile compounding standards. Both contain the same active molecule. The safety profile of the drug itself is the same.

How much does semaglutide cost compared to Wegovy? Brand-name Wegovy costs approximately $1,350 per month without insurance. Compounded semaglutide costs $200 to $500 per month depending on dose and pharmacy. Insurance may cover Wegovy (if your plan includes weight-management drugs) but does not cover compounded semaglutide.

Will my insurance cover semaglutide? Insurance coverage depends on the specific product and indication. Ozempic (semaglutide for diabetes) is widely covered. Wegovy (semaglutide for weight management) is covered by about 30% of commercial plans. Compounded semaglutide is not covered by insurance.

Can I switch from Ozempic to Wegovy? Yes, with provider guidance. The transition typically involves continuing your current Ozempic dose for one more week, then starting Wegovy at the next higher dose in the titration schedule. Your provider will determine the appropriate transition plan based on your current dose and tolerance.

What dose of semaglutide equals Wegovy? Wegovy's maintenance dose is 2.4 mg weekly. If you are taking semaglutide 2.4 mg weekly (compounded or otherwise), that equals the Wegovy dose. Lower doses (0.5 mg, 1 mg) are not equivalent to Wegovy's full therapeutic dose for weight management.

Is semaglutide FDA-approved? Semaglutide as a molecule is the active ingredient in three FDA-approved products: Ozempic, Wegovy, and Rybelsus. Compounded semaglutide is not FDA-approved. FDA approval applies to specific products, not to active ingredients in the abstract.

Do Wegovy and semaglutide have the same side effects? Yes. The side effect profile is determined by the active molecule (semaglutide), not the brand name. Nausea, diarrhea, constipation, and other GLP-1-related side effects occur at similar rates whether you use Wegovy, Ozempic, or compounded semaglutide at equivalent doses.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
6. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017.
7. Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. 2021.
8. Ozempic (semaglutide) injection Prescribing Information. Novo Nordisk. 2017.
9. FDA Drug Shortages Database. U.S. Food and Drug Administration. Accessed April 2026.
10. Federal Food, Drug, and Cosmetic Act Section 503A. Pharmacy Compounding. U.S. Congress. 2013.
11. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. 2023.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Novo Nordisk patent filings. U.S. Patent and Trademark Office. Patents 9,932,390; 10,195,214; 10,369,191.
14. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Advil is a trademark of Haleon. Tylenol is a trademark of Johnson & Johnson. Lipitor is a trademark of Pfizer Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.